Vibha Ravi
Senior Editor, Citeline - Scrip, Pink Sheet. Tweets on pharma, health, environment, other topics of interest to those who read beyond headlines, social media
Articles
-
4 days ago |
insights.citeline.com | Vibha Ravi
Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe GrowthFY28 Inflection Point For BiosimilarsAurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for nowAurobindo Sees Safety On Europe's Shores Amid Fog In The US (Shutterstock)
-
4 days ago |
insights.citeline.com | Vibha Ravi
ASCO: Lupin Presents Early Data On PRMT5 InhibitorASCO sees the debut of Lupin’s PRMT5 inhibitor candidate LRNP7457, currently in Phase I studies in India. While no drug in the class has been approved anywhere for cancer so far, several candidates are in clinical trials. ASCO 2025 Meeting (Alaric DeArment)
-
1 week ago |
insights.citeline.com | Vibha Ravi
Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe GrowthFY28 Inflection Point For BiosimilarsAurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for nowAurobindo Seeks Safety On Europe's Shores Amid Fog In The US (Shutterstock)
-
1 week ago |
insights.citeline.com | Vibha Ravi
Zydus To Continue Mirabegron SalesLooks To World-First Dual Shigella-Typhoid VaccineZydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list. Zydus Is Counting On Key Products, Launches For FY26 Growth (Shutterstock)
-
2 weeks ago |
insights.citeline.com | Vibha Ravi
Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid VaccineZydus expects strong mirabegron sales in FY26 despite US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list Zydus Is Counting On Key Products, Launches For FY26 Growth (Shutterstock)
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 673
- Tweets
- 4K
- DMs Open
- Yes
How to apply for the Global Generics & Biosimilars Award from Generics Bulletin, Citeline - @DaveGenerics shares all the details to nominate, sponsor and attend #awards #Citeline #pharmaceutical @Citeline https://t.co/tZp8019MNl
Taxes, Not Tariffs, Influence US Manufacturing, J&J CEO Says #Tariffs #Trump #Pharmaceuticals #business https://t.co/T2YWaf6Qd6
Pharma deals across the world: A round up brought by my colleague Joseph Haas, who painstakingly puts them together @PharmaScrip #deals #MergersAndAcquisitions #pharmanews https://t.co/nN7sHOLeC9